On Wednesday, June 5, The Heart.org posted this entry, “Rivaroxaban Cuts Stroke Risk in Sinus-Rhythm Heart Failure: COMMANDER-HF.” (Click or Tap).
This is the first publication that implicates an advantage for DOAC therapy in addition to antiplatelet therapy in preventing ischemic strokes and transient ischemic attacks in patients with congestive heart failure with. The key publication is available for purchase from JAMA Cardiology: Greenberg B, Neaton JD, Anker SD et al. Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: A post hoc analysis of the COMMANDER HF trial. JAMA Cardiol. 2019 doi: 10.1001/jamacardio.2019.1049. The Heart.org post points out that the findings indicate the CHA2DS2VASc score can be used to predict DOAC efficacy in the same fashion as CHA2DS2VASc works for non-valvular atrial fibrillation.
No comments here.